Registration partneringONE Program & Speakers

Programme

desire

Desire Collen

Sep 14, 12:30|Teva Hall

Biopharmaceutical Drug Development Between Academia and Industry – Role of Serendipity in the Development for Clinical use of t-PA and Microplasmin

Director of the Molecular Cardiovascular Medicine Group at University of Leuven

Désiré Collen, a world-renowned expert in cardiovascular disease is coming to Life Sciences Baltics 2016
Désiré Collen is a Belgian physician and chemist.  Prof Collen has been recognized as a leading figure in the life sciences industry. He has won numerous awards, including two recent lifetime achievement awards as recognition of his excellent services to the global industry. He has co-authored more than 650 scientific publications, and has co-invented over 20 issued patents and patent applications. During his career, he has proved to be a successful biotech entrepreneur and investor. In 1988 he set up Life Sciences Research Partners (formerly called D Collen Research Foundation), which invests in emerging life sciences companies and promotes scientific research through grants, scholarships and related activities.
What is more, Prof Collen has had a prominent career in drug development. He is a world-renowned expert in cardiovascular disease and was the founder and CEO of ThromboGenics, a biopharmaceutical company dedicated to the development of innovative pharmaceuticals for the prevention and treatment of vascular diseases.  He also directed the Molecular and Cardiovascular Medicine Group at University of Leuven, Belgium. Collen’s laboratory was the first to produce clinical supply of tissue plasminogen activator (t-PA), one of the most effective drugs for thrombolytic therapy of acute myocardial infarction and ischemic stroke.
He graduated as an M.D. at the Katholieke Universiteit Leuven in 1968 and obtained a PhD in chemistry in 1974. He has been the Director at the Centre for Molecular and Vascular Biology, and he was the head of the VIB Department of Transgene Technology and Gene Therapy, K.U.Leuven.
At Life Sciences Baltics 2016 Prof Collen will address the topic of drug development between academia and industry.